Jorge Kattah
Neurology · Peoria, ILNPI 1750489050
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $176 of the $276 with a category attached, or 63.7%. 3 manufacturers reported payments, led by AstraZeneca at 36.3% of the total. That places this record below the midpoint for neurology clinicians in IL, where the typical reported total is $547.
Across 3 payments — averaging $91.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$100
- UCB, Inc.$90
- Argenx US, Inc.$85
Across 114 payments — averaging $5191.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$461K
- Roche Products Limited$57K
- Hoffmann-la Roche Limited$38K
- Chugai Pharmaceutical Co., Ltd.$29K
- F. Hoffmann-la Roche AG$6K
What the payments were for
- Food & beverage$17664%
- Education$10036%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $100 |
| UCB, Inc. | 1 | $90 |
| Argenx US, Inc. | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$100
How this compares
$276 in reported general payments places this provider in the 40th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dimethyl Fumarate | 11 | $49,927 |
| Pyridostigmine Bromide | 30 | $2,061 |
| Azathioprine | 27 | $1,885 |
| Carbamazepine ErCarbamazepine | 12 | $1,843 |
| Acetazolamide | 20 | $1,383 |
| Memantine Hcl | 15 | $1,205 |
| Gabapentin | 19 | $719 |
| Prednisone | 78 | $443 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $197 |
| Ondansetron Hcl | 21 | $55 |
| Clonazepam | 16 | $35 |
Paid to pharmacies, not to this prescriber.
Other neurology in Peoria
- Reuben ValenzuelaPeoria$590K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.